Luminex Stock Price, Forecast & Analysis (NASDAQ:LMNX)

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex announced a quarterly dividend on Wednesday, July 31st. Investors of record on Thursday, September 26th will be paid a dividend of $0.09 per share on Thursday, October 17th. This represents a $0.36 annualized dividend and a yield of 1.81%. The ex-dividend date is Wednesday, September 25th. This is a boost from Luminex's previous quarterly dividend of $0.06. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings results on Monday, November, 4th. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.09. The medical instruments supplier earned $78.67 million during the quarter, compared to the consensus estimate of $81.75 million. Luminex had a negative net margin of 2.93% and a negative return on equity of 2.38%. The firm's revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.04 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Luminex.

3 analysts have issued 1 year price objectives for Luminex's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's stock price to reach $26.50 in the next year. This suggests a possible upside of 33.1% from the stock's current price. View Analyst Price Targets for Luminex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Media coverage about LMNX stock has been trending somewhat positive on Thursday, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Luminex earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Luminex.

Luminex saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 866,300 shares, a drop of 9.3% from the September 30th total of 954,700 shares. Based on an average daily trading volume, of 180,500 shares, the days-to-cover ratio is presently 4.8 days. Currently, 2.1% of the shares of the company are sold short. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Mondi (MNDI), Alphabet (GOOG), Micron Technology (MU), Nektar Therapeutics (NKTR), Rocket Pharmaceuticals (RCKT), Caterpillar (CAT), Verizon Communications (VZ), Intel (INTC) and Ligand Pharmaceuticals (LGND).

Luminex's stock is owned by a number of of institutional and retail investors. Top institutional investors include Investment Management of Virginia LLC (2.10%), Hancock Whitney Corp (0.49%), Russell Investments Group Ltd. (0.47%), Great Lakes Advisors LLC (0.41%), Rhumbline Advisers (0.32%) and Fisher Asset Management LLC (0.18%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., Russell Investments Group Ltd., Hancock Whitney Corp, Fisher Asset Management LLC and Investment Management of Virginia LLC. View Insider Buying and Selling for Luminex.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Benjamin F. Edwards & Company Inc., Tocqueville Asset Management L.P., Great Lakes Advisors LLC, State of Alaska Department of Revenue, Bridge City Capital LLC, SG Americas Securities LLC, Rhumbline Advisers and California Public Employees Retirement System. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $19.91.

Luminex has a market capitalization of $896.99 million and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]